Progyny, Inc. $PGNY Position Boosted by WINTON GROUP Ltd

WINTON GROUP Ltd boosted its holdings in Progyny, Inc. (NASDAQ:PGNY) by 266.7% during the 2nd quarter, Holdings Channel reports. The fund owned 251,834 shares of the company’s stock after acquiring an additional 183,163 shares during the quarter. WINTON GROUP Ltd’s holdings in Progyny were worth $7,260,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in the business. Engineers Gate Manager LP increased its holdings in shares of Progyny by 5.6% during the second quarter. Engineers Gate Manager LP now owns 152,757 shares of the company’s stock valued at $4,404,000 after purchasing an additional 8,156 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in Progyny in the second quarter worth about $74,000. IFP Advisors Inc grew its position in Progyny by 376.0% in the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock valued at $57,000 after buying an additional 1,549 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Progyny during the 2nd quarter valued at about $1,705,000. Finally, Allworth Financial LP increased its stake in Progyny by 71.7% during the 2nd quarter. Allworth Financial LP now owns 3,259 shares of the company’s stock valued at $94,000 after buying an additional 1,361 shares during the period. Institutional investors own 94.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on PGNY shares. Citizens Jmp upped their price target on shares of Progyny from $31.00 to $33.00 and gave the stock a “market outperform” rating in a research note on Tuesday. Wall Street Zen lowered shares of Progyny from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. Barclays dropped their target price on Progyny from $34.00 to $30.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 12th. JPMorgan Chase & Co. upped their target price on Progyny from $27.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, August 21st. Finally, Canaccord Genuity Group set a $35.00 price target on Progyny in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.36.

Progyny Trading Down 0.1%

Shares of Progyny stock opened at $27.12 on Thursday. Progyny, Inc. has a 52 week low of $16.10 and a 52 week high of $33.06. The stock has a market cap of $2.08 billion, a PE ratio of 29.48, a price-to-earnings-growth ratio of 1.87 and a beta of 0.99. The company’s 50-day moving average price is $28.83 and its two-hundred day moving average price is $23.95.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.22. The company had revenue of $350.51 million during the quarter, compared to analyst estimates of $349.05 million. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.19 EPS. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, equities analysts predict that Progyny, Inc. will post 1.25 EPS for the current fiscal year.

Progyny declared that its board has initiated a stock buyback program on Tuesday, May 26th that allows the company to repurchase $200.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 10.3% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

Progyny Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.